BioCentury
ARTICLE | Financial News

Tot raises $102M series B

August 8, 2018 8:32 PM UTC

Cancer company Tot Biopharm Co. Ltd. (Suzhou, China) raised $102 million in a series B round. Participants included China Universal (Cayman) GP Ltd. and other investors as well as existing investors Center Laboratories Group, Vivo Capital, Chengwei Capital, Yuanta Financial Holdings Group and Cathay Capital.

Tot's pipeline includes TAB008, which is in Phase III testing. TAB008 is a biosimilar of cancer drug Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY)...

BCIQ Company Profiles

Tot Biopharm Co. Ltd.